AU · rank #6 · 2026-06-03
LEGN
NASDAQ · $6.74B
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.996 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.12 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.099 |
| Analyst upside Consensus target $55.39 | +52.7% |
| Momentum acceleration 3-month minus 12-month momentum. | +97.49% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.45 |
| Gross margin TTM | +20.0% |
| 52w high | $45.30 |
| Market cap | $6.74B |
The AI research card
Independent qualitative review of each pick before the order is placed.
Summary
Legend Biotech is a clinical-stage/commercial cell-therapy company generating near-term revenue from Carvykti (BCMA CAR-T for multiple myeloma) via J&J partnership, with pipeline expansion and manufacturing scale-up as key value drivers.
Rationale
52.7% analyst upside, 4.45/5 rating, and 97.5% momentum acceleration reflect consensus optimism on Carvykti label-expansion potential and capacity-constrained market dynamics, supported by recent Q1 2025 growth and ASCO/EBMT clinical data reinforcing durability.
Material risks
- 1Single-asset concentration risk—Carvykti represents substantially all revenue; any regulatory setback, safety signal, or manufacturing disruption would directly impair valuation and J&J partnership economics.
- 2Manufacturing bottleneck and supply-chain execution risk—autologous CAR-T therapies require complex, specialized facilities and raw-material sourcing; capacity constraints could limit addressable market penetration and pricing power if competitors (Abecma, bispecific antibodies) scale faster.
Verdict reasoning
two_stage score=+3/3 verdicts={'openai': 'PROCEED', 'claude': 'PROCEED', 'gemini': 'PROCEED'} brief=caller-supplied